Yongkui Lu

858 total citations
20 papers, 657 citations indexed

About

Yongkui Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yongkui Lu has authored 20 papers receiving a total of 657 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Yongkui Lu's work include Lung Cancer Research Studies (6 papers), Advanced Breast Cancer Therapies (4 papers) and Sarcoma Diagnosis and Treatment (4 papers). Yongkui Lu is often cited by papers focused on Lung Cancer Research Studies (6 papers), Advanced Breast Cancer Therapies (4 papers) and Sarcoma Diagnosis and Treatment (4 papers). Yongkui Lu collaborates with scholars based in China and Singapore. Yongkui Lu's co-authors include Aihua Tan, Shusen Wang, Nong Li, Jianmin Song, Weimin Xie, Guowen Wang, Xia Zhu, Guofan Qu, Yihebali Chi and Meiling Liu and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Yongkui Lu

19 papers receiving 653 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yongkui Lu China 11 350 259 220 145 108 20 657
Anastasios Kyriazoglou Greece 13 191 0.5× 217 0.8× 222 1.0× 130 0.9× 57 0.5× 60 610
Francesca Simionato Italy 17 455 1.3× 199 0.8× 290 1.3× 199 1.4× 49 0.5× 31 794
Fangchao Zheng China 9 425 1.2× 278 1.1× 272 1.2× 203 1.4× 79 0.7× 33 800
Dengfeng Ren China 11 535 1.5× 346 1.3× 180 0.8× 149 1.0× 71 0.7× 47 825
Tomoyuki Aoyama Japan 14 229 0.7× 306 1.2× 188 0.9× 110 0.8× 33 0.3× 38 652
Yuji Tada Japan 16 163 0.5× 454 1.8× 326 1.5× 120 0.8× 45 0.4× 38 855
Alexandros Nomikos Greece 16 348 1.0× 114 0.4× 232 1.1× 180 1.2× 56 0.5× 29 649
A. Reinacher-Schick Germany 11 441 1.3× 146 0.6× 175 0.8× 149 1.0× 53 0.5× 46 636
Yawei Yuan China 14 241 0.7× 190 0.7× 314 1.4× 218 1.5× 85 0.8× 25 679
F. De Vita Italy 11 405 1.2× 196 0.8× 198 0.9× 220 1.5× 47 0.4× 37 691

Countries citing papers authored by Yongkui Lu

Since Specialization
Citations

This map shows the geographic impact of Yongkui Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongkui Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongkui Lu more than expected).

Fields of papers citing papers by Yongkui Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongkui Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongkui Lu. The network helps show where Yongkui Lu may publish in the future.

Co-authorship network of co-authors of Yongkui Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Yongkui Lu. A scholar is included among the top collaborators of Yongkui Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongkui Lu. Yongkui Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Jiong, Jian Zhang, Man Li, et al.. (2024). A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1047–1047. 1 indexed citations
2.
Lu, Yongkui, Lixia Li, Meiting Chen, et al.. (2024). Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study. BMC Cancer. 24(1). 1214–1214.
3.
Xu, Fei, Yongkui Lu, Caiwen Du, et al.. (2024). Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. npj Breast Cancer. 10(1). 45–45. 3 indexed citations
4.
5.
Wang, Hongxue, Yan Liu, Wuning Zhong, et al.. (2021). Efficacy and safety of continuous infusion of Rh-endostatin combined with platinum-based chemotherapy for advanced triple-negative breast cancer. Annals of Palliative Medicine. 10(12). 12101–12112. 4 indexed citations
6.
Luo, Tao, Aihua Tan, Lixia Duan, et al.. (2020). Mesenchymal Stem Cell-Secreted Exosome Promotes Chemoresistance in Breast Cancer via Enhancing miR-21-5p-Mediated S100A6 Expression. Molecular Therapy — Oncolytics. 19. 283–293. 63 indexed citations
7.
Wang, Hongxue, Han Wang, Hao Mo, et al.. (2020). A three-gene signature based on tumour microenvironment predicts overall survival of osteosarcoma in adolescents and young adults. Aging. 13(1). 619–645. 18 indexed citations
8.
Liu, Yan, Nong Li, Aihua Tan, et al.. (2020). Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4/NF-κB pathway. Aging. 12(7). 6058–6066. 24 indexed citations
9.
Chi, Yihebali, Yang Yao, Zhiwei Fang, et al.. (2020). Evaluation of thyroid-stimulating hormone-increased, hypertriglyceridemia and proteinuria as markers of anlotinib efficacy in advanced soft tissue sarcoma.. Journal of Clinical Oncology. 38(15_suppl). e23548–e23548. 1 indexed citations
10.
Duan, Lixia, Yongkui Lu, Weimin Xie, et al.. (2020). Leptin promotes bone metastasis of breast cancer by activating the SDF-1/CXCR4 axis. Aging. 12(16). 16172–16182. 22 indexed citations
11.
Fang, Zhiwei, Yang Yao, Jianqiang Cai, et al.. (2020). Efficacy of anlotinib in advanced soft tissue sarcoma by age, gender, and ECOG performance status.. Journal of Clinical Oncology. 38(15_suppl). e23562–e23562. 1 indexed citations
12.
Xu, Xueyuan, et al.. (2019). Research on Reactive Power Compensation System of Offshore Wind Farm. 5100–5105. 4 indexed citations
13.
Chi, Yihebali, Zhiwei Fang, Xiaonan Hong, et al.. (2018). Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research. 24(21). 5233–5238. 245 indexed citations
14.
Chi, Yihebali, Yang Yao, Shusen Wang, et al.. (2018). Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.. Journal of Clinical Oncology. 36(15_suppl). 11503–11503. 49 indexed citations
15.
Qin, Jie, Yan Liu, Yongkui Lu, et al.. (2017). Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression. Scientific Reports. 7(1). 104 indexed citations
16.
Yu, Yang, Yan Liu, Chen Zong, et al.. (2016). Mesenchymal stem cells with Sirt1 overexpression suppress breast tumor growth via chemokine-dependent natural killer cells recruitment. Scientific Reports. 6(1). 35998–35998. 27 indexed citations
17.
Chi, Yihebali, Yongkun Sun, Jianqiang Cai, et al.. (2016). Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.. Journal of Clinical Oncology. 34(15_suppl). 11005–11005. 21 indexed citations
18.
Chen, Dongni, Weimin Xie, Yongkui Lu, et al.. (2016). Gene Polymorphisms of TLR2 and TLR3 in HBV Clearance and HBV-Related Hepatocellular Carcinoma in a Chinese Male Population. The International Journal of Biological Markers. 32(2). 195–201. 15 indexed citations
19.
Mo, Ning, Yongkui Lu, Weimin Xie, et al.. (2014). Inhibition of autophagy enhances the radiosensitivity of nasopharyngeal carcinoma by reducing Rad51 expression. Oncology Reports. 32(5). 1905–1912. 47 indexed citations
20.
Ning, Shufang, Jilin Li, Changhong Wei, et al.. (2014). Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.. PubMed. 7(12). 8740–7. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anastasios Kyriazoglou Breakdown of academic impact, for papers by Francesca Simionato Breakdown of academic impact, for papers by Fangchao Zheng Breakdown of academic impact, for papers by Dengfeng Ren Breakdown of academic impact, for papers by Tomoyuki Aoyama Breakdown of academic impact, for papers by Yuji Tada Breakdown of academic impact, for papers by Alexandros Nomikos Breakdown of academic impact, for papers by A. Reinacher-Schick Breakdown of academic impact, for papers by Yawei Yuan Breakdown of academic impact, for papers by F. De Vita
Rankless by CCL
2026